2 Last year, a decade after Piramal Enterprises Ltd (PEL), erstwhile Piramal Healthcare, sold its domestic formulation business to Abbott Laboratories for US$3.8 billion (probably the biggest pharma deal in India), it sealed another deal in its pharma business. In June 2020, it announced the stake sale of 20% equity in Piramal Pharma Ltd (PPL), the wholly-owned subsidiary of Piramal... Premium Content